Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal-dominant vascular disorder that affects approximately 1 in 5,000 individuals. It is characterized by dysplasia of both large vessels that include arteriovenous malformations (AVM) and of small vessels that include telangiectasias. Debilitating epistaxis is the most common symptom of HHT, but the disease often affects multiple organs and requires a multisystem and multidisciplinary approach to successfully manage these patients. The purpose of this panel is to provide an overview of the multidisciplinary approach use to diagnose, evaluate, and treat patients with HHT. We will utilize the expertise of a nationally known otolaryngologist, pulmonologist, and interventional radiologist to discuss novel pharmacologic and surgical treatment options available for HHT-related epistaxis and multiorgan disease in a case-based format. Lastly, this panel will also demonstrate the importance of the team approach while treating patients with multi-organ disease and discuss how multidisciplinary care results in significant better outcomes.